1. Home
  2. NVNI vs IXHL Comparison

NVNI vs IXHL Comparison

Compare NVNI & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

N/A

Current Price

$1.33

Market Cap

12.9M

Sector

N/A

ML Signal

N/A

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

N/A

Current Price

$5.88

Market Cap

97.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NVNI
IXHL
Founded
2019
2001
Country
Brazil
Australia
Employees
618
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
97.6M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
NVNI
IXHL
Price
$1.33
$5.88
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
83.8K
4.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$12,000.00
Revenue This Year
$6.67
N/A
Revenue Next Year
$26.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.11
52 Week High
$4.94
$5.45

Technical Indicators

Market Signals
Indicator
NVNI
IXHL
Relative Strength Index (RSI) 37.97 90.18
Support Level $1.10 $0.31
Resistance Level $1.64 N/A
Average True Range (ATR) 0.14 0.37
MACD 0.04 0.40
Stochastic Oscillator 40.00 91.05

Price Performance

Historical Comparison
NVNI
IXHL

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: